NanoVibronix, Inc. (NASDAQ:NAOV) is a medical device company founded in 2003 and headquartered in Elmsford, New York. The company specializes in developing and manufacturing noninvasive ultrasound-based therapeutic devices that target biofilm prevention, wound healing, and pain management. Through its Israeli subsidiary NanoVibronix Ltd., the company has developed a portfolio of ultrasound patch technologies that leverage low-frequency surface acoustic waves to provide therapeutic benefits. Since going public in 2015, NanoVibronix has focused on commercializing its proprietary ultrasound platform across multiple medical applications, selling products both directly to patients and through distributor networks in the United States, Israel, Europe, India, and other international markets.
$1.03
+0.00%Price chart
Sep 11Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12
Key dataOct 12, 2026
Open$0.35
From 52W high−98.28%
Volume50800.00
Market cap$951429.54
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataOct 12, 2026
Open
$0.35
From 52W high
−98.28%
Volume
50800.00
Market cap
$951429.54
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
24.4
MomentumView details →
1D Return
+0.00%
YTD Return
−98.73%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
ENvue Medical signed a multi-year exclusive distribution agreement with Peak Medical for UroShield across the United Kingdom and Republic of Ireland, with minimum purchase commitments of approximately $2.6 million.63d agoENvue Medical entered into a securities purchase agreement with an institutional investor for an equity facility of up to $50 million to support commercial growth, technology expansion, and strategic acquisitions.69d agoENvue Medical, Inc. amended its Series H Purchase Agreement with the same investor, increasing the total Additional Investment Rights and requiring the investor to exercise a minimum amount of rights following shareholder approval.69d ago